2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…2018 American Transplant Congress
The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis
Introduction: Current treatment strategies for antibody-mediated rejection (AMR) in kidney transplantation are based on low quality data from a small number of controlled trials. Novel…2018 American Transplant Congress
Complement Fixing Donor-Specific Antibodies Are Associated with Increased Risk of Chronic Lung Allograft Dysfunction after Lung Transplantation
1University of Pittsburgh, Pittsburgh, PA; 2Temple University, Philadelphia, PA.
Purpose: Survival among lung transplant recipients (LTRs) remains poor compared to other solid organs.The presence of donor-specific antibodies (DSA) directed against donor human leukocyte antigen…2018 American Transplant Congress
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
Surgery, University of Wisconsin, Madison, WI.
Introduction: Basiliximab, alemtuzumab, and thymoglobulin are the most commonly used induction agents in the US. While many centers use depleting antibody induction therapy in patients…2018 American Transplant Congress
ABO-Incompatibility Lower Incidence of DSA-Induced Antibody-Mediated Rejection
Introduction:Donor-specific anti-HLA antibody (DSA) and Anti-ABO antibody are major barriers for successful kidney transplantation. Limited data are available about the existences of both DSA and…2018 American Transplant Congress
Successful Desensitization with Carfilzomib-Based Regimen to Facilitate Lung Transplantation: Initial Experience
1University of Pittsburgh, Pittsburgh, PA; 2Temple University, Philadelphia, PA.
Purpose:We describe the successful desensitization of highly sensitized lung transplant candidates (LTCs) using plasma exchange (PLEX),intravenous immunoglobulin G(IVIg),and carfilzomib.Methods:5-patient case series of successful desensitization of…2018 American Transplant Congress
The Impact of Donor Specific Alloantibodies on Long-Term Outcomes of Liver Re-Transplantation
Despite reports that associate donor specific antibody (DSA) with rejection after liver transplantation, grafts are still allocated according to blood group (ABO) but not human…2018 American Transplant Congress
Mid-Term Outcome of Donor Specific Antibody Positive Deceased Donor Kidney Transplantation with Peri-Transplant Desensitization
Donor specific HLA-antibodies (DSA) remain a large barrier to successful kidney transplantation and there is a limited knowledge about desensitization strategies in deceased donor programs.Anti…2018 American Transplant Congress
Targeting Plasma Cells with Anti-CD38mAb (Daratumumab) and CXCR4 Antagonist (Plerixafor) for Desensitization
1Surgery, Duke University, Durham, NC; 2Surgery, Mayo Clinic, Rochester, MN.
[Introduction] Sensitized patients comprise a significant portion (30%) of candidates on the transplant waiting list. Unfortunately for sensitized patients, the presence of donor-specific antibodies (DSA)…2018 American Transplant Congress
Kidney Allograft Vascular Disease Post-Transplant (KTX): Risk Factors and Implications
1Medicine, Mayo Clinic, Rochester, MN; 2Pathology, Mayo Clinic, Rochester, MN.
Background: Over time grafts develop arteriosclerosis (ART)and arteriolar hyalinosis (AH). Previous studies associated AH with calcineurin inhibitors (CNI), diabetes (DM), kidney age and hypertension. Other…
American Transplant Congress abstracts